Datapoint: FDA Approves Sun Pharma’s JAK Inhibitor

The FDA last week approved Sun Pharma’s oral JAK inhibitor Leqselvi (deuruxolitinib) for the treatment of severe alopecia areata in adult patients, becoming the third JAK therapy in the rapidly growing space. Eli Lilly’s Olumiant (baricitinib) in 2022 became the first systemic therapy available to treat alopecia areata. The JAK inhibitor currently holds covered or better status for 70% of all insured lives under the pharmacy benefit, though utilization management (UM) restrictions are required for most patients. It was followed in 2023 by Pfizer’s JAK inhibitor Litfulo (ritlecitinib), which holds 64% covered or better status, also largely with UM applied.

SOURCE: MMIT Analytics, as of 7/29/24

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today